Overview

Optical Coherence Tomography: Glatiramer in Clinically Isolated Syndrome or Early Relapsing Remitting Multiple Sclerosis (MS)

Status:
Unknown status

Trial end date:
2012-06-01

Target enrollment:

Participant gender:

Summary

This is a study in patients with clinically isolated syndrome (CIS) and early relapsing remitting multiple sclerosis (RRMS) to assess the effects of glatiramer acetate (GA) subcutaneously on the condition of the optical nerve in comparison to no medicinal therapy during 12 months and to assess the use of Optical Coherence tomography (OCT), a non-invasive ophthalmological technique, in daily practice as an alternative to magnetic resonance imaging (MRI) scanning for follow-up of these patients.

Phase:

Phase 4

Details

Lead Sponsor:

Amphia Hospital

Collaborators:

Sanofi
TEVA Pharmachemie

Treatments:

(T,G)-A-L
Glatiramer Acetate